Hi Titan,
I have been looking at some others (I didn't dig that deep) - however your question "if I found any with small listed biostocks like RAC". From what I can see, Agios was a small unlisted biostock, like RAC. They had been performing preclinical work prior to the partnership with Celgene and that had been showing promising results. The Celgene partnership was worth US$351.7 to Agios (who still distribute directly in the US) - not including NPAT royalty payments for Celgene to distribute globally. This included a US$120m payment for Agios to commence trials (which from memory were subsequently approved by the FDA straight out of stage 2).
A question I would ask you is; why do you place so little value on RAC? Why do you only expect an upfront payment of $10m? Celgene took on a fair bit of risk (i.e. Tibsovo failing), however; they also wound up with quite the deal. I don't know the complete distribution of sales so I can only speculate; Tibsovo is expected to hit peak sales of US$300m. If you assume half of those sales occur outside of the US that is US$150m for Celgene (minus royalities).
For the sake of round numbers; say Tibsovo generates Celgene US100m after royalty payments to Agios. They aquired the right to distribute it for US$351.7... bargain. I f you consider RAC's potential market I'd argue that US350m for global distribution rights to Bisantrene would be too bloody cheap.
Quick (un-referenced) response as I'm off to the pub. DYOR.
Edit: Agios didn't dilute the company - they just reduced earning potential.
Responsibilities of the team, page-95
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$2.02 |
Change
0.010(0.50%) |
Mkt cap ! $343.9M |
Open | High | Low | Value | Volume |
$2.04 | $2.09 | $1.92 | $768.4K | 380.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 484 | $2.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.02 | 3251 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 484 | 2.000 |
1 | 2319 | 1.985 |
1 | 252 | 1.980 |
1 | 16000 | 1.975 |
2 | 6132 | 1.970 |
Price($) | Vol. | No. |
---|---|---|
2.020 | 3251 | 2 |
2.040 | 500 | 1 |
2.050 | 10000 | 1 |
2.070 | 994 | 1 |
2.080 | 2450 | 1 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online